Antipsychotic medications are widely prescribed and carry a variable propensity to cause weight gain and its attendant sequelae -hyperglycaemia, hypertension and hyperlipidaemia. These metabolic risks, along with smoking and poor lifestyle habits, occur between two and five times more often in patients with psychosis than in the general population. early detection and intervention for cardiometabolic risks, and a judicious tailoring of the use of antipsychotic medications can help to improve long-term outcomes in these patients.
effects. A major problem of the older antipsychotics is the neurological effects such as parkinsonism, dystonia, dyskinesia and akathisia. With some of the newer 'atypical' antipsychotics, obesity and other risk factors for cardiovascular and metabolic disease are a problem. Although these metabolic effects can also be caused by the older antipsychotics, they have assumed greater importance as the incidence of premature mortality from preventable cardiovascular disease and diabetes has become increasingly evident.
It is estimated that the life expectancy of patients with schizophrenia will be shortened by up to 25 years compared to the general population, even after controlling for the risk of suicide. 1 At the same time, age-adjusted rates of cardiovascular death in the general population have been falling. For patients with schizophrenia or bipolar disorder as well as diabetes, the chances of premature death are significantly higher compared to matched persons with diabetes alone. 2 Clearly the illness and its treatment may be contributing to the development of metabolic risk.
Psychosis and cardiometabolic risk factors
Risk factors for cardiovascular disease are over-represented in people with psychosis. In a West Australian study of an adult community psychiatric service, over half of people with severe mental illness had metabolic syndrome. 3 This was broadly in agreement with a database of chronic psychiatric patients from Victorian and NSW community and inpatient services (www.ccchip.com.au). Up to 89% of patients had an excess waist circumference. Females had higher rates of obesity.
It is estimated that the risk of diabetes in the people with psychosis is 2-6 times higher than the rest of the population, depending on age (the young have accelerated risk rates). Raised triglycerides have been found in up to 53% of people with psychosis. 3 High blood pressure (≥130 mmHg systolic or ≥85 mmHg diastolic in those with diabetes or at risk, as defined by the International Diabetes Federation, www.idf.org) was found in up to two-thirds of patients who are screened. 3 This represents a rate at least twice that of the healthy population. Gender differences are common with males being more likely to have elevated blood pressure.
In the West Australian study, 64% of patients with psychosis smoked cigarettes. 3 This is compared to 25-30% of the general population. This incidence appears to be similar across western countries over time. 
Antipsychotics and cardiometabolic risk factors
There remains considerable debate as to the degree that antipsychotics contribute to cardiometabolic risks. In the short term there appears a clear hierarchy of drugs that promote weight gain, but in the longer term (and generally, patients with persistent psychosis are on lifelong maintenance therapy) it is less clear ( Table 1) . 5 Clozapine has the highest potential to cause 
Assessing cardiometabolic risk factors -how often?
It is important to start monitoring patients immediately after they have started antipsychotics, then every three months during the first year and every six months after that.
Lifestyle interventions
Recommended lifestyle changes are the same for patients taking antipsychotics as they are for the general population.
A package of care comprising aerobic exercise, weight loss, smoking cessation, consuming a high soluble fibre diet, reducing alcohol intake and potentially adding omega-3 fish oils may lead to significant improvements in cardiovascular risks.
Modifying lifestyle, including diet and exercise, is difficult in any population. However, the response of patients with psychosis may be more vigorous than anticipated and participation rates in structured programs may be high. 6 
Pharmacotherapeutic interventions
Should lifestyle management fail to provide adequate control of the developing risks, a number of additional strategies should be considered.
Switching antipsychotics
The potential of antipsychotics to cause metabolic effects varies (Table 1 ). In many cases it is very difficult to find an optimal antipsychotic drug for the individual. 8 If these are not absolutely required, they should be either discontinued or substituted for drugs with a lower potential to cause weight gain.
Drugs for metabolic illness
The use of standard pharmaceutical approaches for psychiatric 
Adherence
Up to two-thirds of patients with schizophrenia are nonadherent or partially adherent to their antipsychotic treatments.
Adherence is reduced in those who take other medications and adherence rates are lower for hypoglycaemics and antihypertensives than for antipsychotics. 10 Patient counselling to promote adherence should be a mainstay of all interventions offered to patients with metabolic comorbidity, just as it is an essential component of antipsychotic management. The key to success is regular follow-up with the general practitioner, itself an issue of partial adherence.
If diabetes has been diagnosed, engaging the patient with appropriate specialist services such as a diabetes nurse educator may help with adherence.
Bariatric surgery
In a small case series, outcomes after bariatric surgery for morbidly obese patients with schizophrenia were similar to controls. 11 There are few studies that have carefully considered longer-term outcomes, or formulated consent guidelines for this population. However, it remains an option for those with severe complicated obesity where postoperative medical review is available and patient adherence is adequate. 12
Conclusion
The rates of metabolic disorder and general cardiovascular risks 
